Spyre halts RA program for anti-TL1A candidate after Phase 2 disappointment
Spyre Therapeutics is deprioritizing its anti-TL1A antibody for rheumatoid arthritis after the drug failed to meet the company's threshold for success in a mid-stage trial. The decision casts doubt on the broader potential of the candidate, though the company has not disclosed full results.
Expanded Detail
EXPANDED:
Spyre Therapeutics has decided to deprioritize its anti-TL1A antibody program for rheumatoid arthritis after the candidate failed to meet the company's internal success threshold in a Phase 2 trial. The company has not yet disclosed full trial results
Expanded detail and Context are AI-generated analysis; the linked article remains the authoritative source.
Related stories
Bausch + Lomb pushes dry eye therapy to Phase 3 after Phase 2 miss · Drug development
Alumis' experimental TYK2 inhibitor misses primary endpoint in mid-stage lupus study · Drug development
AstraZeneca's experimental heart failure pill yields mixed but encouraging phase 2 data · Drug development
Teva's Anti-IL-15 Antibody Shows Promise in Celiac Disease Trial · Drug development
This summary is AI-generated and original to Mobble; the linked article is the authoritative source.
Original headline: “Spyre drops rheumatoid arthritis hopes for anti-TL1A drug after modest Phase 2 data.” Browse more stories.